Revenue At A Point In Time was Legend Biotech’s largest revenue line in fiscal 2024, bringing in $563.91M of $627.24M (90%).
| Timing of transfer of goods or services [axis] | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Revenue At A Point In Time | $117.01M | $285.14M | $563.91M |
| Revenue Over Time | — | — | $63.33M |
| Total | $117.01M | $285.14M | $627.24M |
Legend Biotech brought in $627.24M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. Legend Biotech regrouped these revenue lines after fiscal 2023, so the total does not compare directly with that year's $285.14M. Revenue At A Point In Time was the largest at $563.91M (89.9%), ahead of Revenue Over Time at $63.33M (10.1%).
Legend Biotech began breaking out Revenue Over Time in fiscal 2024, when it brought in $63.33M.
Janssen Agreement was Legend Biotech’s largest revenue line in fiscal 2021, bringing in $65.40M of $68.80M (95%).
| Categories of related parties [axis] | FY 2020 | FY 2021 |
|---|---|---|
| Janssen Agreement | $75.00M | $65.40M |
| Nanjing Probio Biotech Co., Ltd | — | $3.40M |
| Total | $75.00M | $68.80M |
Legend Biotech brought in $68.80M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. Legend Biotech regrouped these revenue lines after fiscal 2020, so the total does not compare directly with that year's $75.00M. Janssen Agreement was the largest at $65.40M (95.1%), ahead of Nanjing Probio Biotech Co., Ltd at $3.40M (4.9%).
Legend Biotech began breaking out Nanjing Probio Biotech Co., Ltd in fiscal 2021, when it brought in $3.40M.
As Previously Reported was Legend Biotech’s largest revenue line in fiscal 2020, bringing in $75.68M of $75.00M (101%).
| Total Restatement Impacts | FY 2019 | FY 2020 |
|---|---|---|
| As Previously Reported | $57.26M | $75.68M |
| Total Adjustments | $2.72M | -$676.00K |
| Total | $59.98M | $75.00M |
Legend Biotech brought in $75.00M from its two revenue lines in fiscal 2020, the year ended December 31, 2020. That was up 25.0% from $59.98M in fiscal 2019. As Previously Reported was the largest at $75.68M (100.9%).
The total is net of Total Adjustments, which took $676.00K off revenue in fiscal 2020.
Legend Biotech (LEGN) reports its revenue by timing of transfer of goods or services [axis], by categories of related parties [axis] and by total restatement impacts. In fiscal 2024, Revenue At A Point In Time was its largest revenue line, bringing in $563.91M (89.9% of the total), followed by Revenue Over Time at $63.33M (10.1%).
Revenue At A Point In Time was Legend Biotech's largest revenue line in fiscal 2024, bringing in $563.91M, or 89.9% of the $627.24M total across its two revenue lines.
Every figure comes from Legend Biotech's annual financial filings, as reported. Each line keeps the name Legend Biotech gives it, and years follow its fiscal calendar.
Legend Biotech's revenue by timing of transfer of goods or services [axis] goes back to fiscal 2022, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.